Neumora Reports Q4/FY25 Results, Strong Cash Runway, & Positive Pipeline Progress; NMRA-215 Study Delayed

summarizeSummary

Neumora Therapeutics reported Q4 and full-year 2025 financial results, showcasing a strong cash position expected to fund operations into Q3 2027, alongside positive clinical updates for multiple pipeline programs, though one program experienced a toxicology-related delay.

check_boxKey Events

• Strong Cash Position and Runway

  Neumora reported $182.5 million in cash, cash equivalents, and marketable securities as of December 31, 2025, expected to fund operations into the third quarter of 2027.

• Positive NMRA-511 Phase 1b Data

  New data from a pre-specified analysis of the Phase 1b study for NMRA-511 in Alzheimer's disease agitation demonstrated strong effect sizes, reinforcing its potential best-in-class profile.

• Navacaprant KOASTAL Studies Fully Enrolled

  The KOASTAL-2 and -3 studies for navacaprant were fully enrolled in Q1 2026, with a joint topline data readout anticipated in the second quarter of 2026.

• NMRA-898 Designated Lead Program

  NMRA-898 was selected as the lead program in the M4 franchise for schizophrenia, based on promising clinical results from an ongoing Phase 1 study, including a long half-life and favorable tolerability.

auto_awesomeAnalysis

Neumora Therapeutics announced its fourth quarter and full year 2025 financial results, highlighting a robust cash position of $182.5 million, which is expected to fund operations into the third quarter of 2027. This provides significant financial stability for the clinical-stage biopharmaceutical company. The company also reported positive new Phase 1b data for NMRA-511 in Alzheimer's disease agitation, reinforcing its potential. Additionally, the KOASTAL-2 and -3 studies for navacaprant are fully enrolled with topline data expected in Q2 2026, and NMRA-898 was designated as the lead program in the M4 franchise based on promising Phase 1 results. However, the NMRA-215 obesity program faced a setback with unexpected adverse findings in a 13-week rat toxicology study, leading to a delay in clinical initiation to Q1 2027 as the study is being repeated. Despite this delay, the overall pipeline progress and strong financial runway present a positive outlook.